Engineered brain-targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma
An acid-cleavable Tf-modified engineering exosome-based brain-targeting delivery system (ACTE) was proposed using metabolic glycoengineering and bioorthogonal click chemistry, enabling co-delivery of siTGF-β and DOX for GBM treatment. ACTE was featured by higher BBB transcytosis efficiency and hierarchical targeting delivery to GBM cells. Ds@ACTE effectively reprogrammed the immunosuppressive GBM microenvironment, reducing chemoresistance and enhancing anti-GBM immune …